Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.

The gel is safe and effective for treating oral mucositis from chemotherapy and radiation.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

The new delivery system improved hair growth in alopecia treatment.

Overexpressing COX-2 in mice skin reduces skin tumor development.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.

Nanocarriers can improve skin treatments after cancer therapy by enhancing antioxidant delivery and effectiveness.

YAP and TAZ proteins are necessary for the development of two types of skin cancer.

Topical calcitriol appears safe and may reduce hair loss during chemotherapy.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

A 25-year-old man with multiple skin tumors was successfully treated with acitretin and methotrexate.

SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.

EGFR inhibitors can cause unusual localized hair growth.

A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.

Sorafenib may cause hair loss in a way similar to alopecia areata.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.

Mycophenolate mofetil may safely help restore skin color in depigmentation conditions.